Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Share-based Compensation (2018 - 2026)

10x Genomics' Share-based Compensation history spans 8 years, with the latest figure at $25.2 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 22.5% to $25.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.1 million, a 22.47% decrease, with the full-year FY2025 number at $109.1 million, down 22.47% from a year prior.
  • Share-based Compensation hit $25.2 million in Q4 2025 for 10x Genomics, roughly flat from $25.3 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TXG hit a ceiling of $45.7 million in Q2 2023 and a floor of $16.2 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $32.5 million across 5 years, with a median of $33.0 million in 2022.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 140.79% in 2021 and later dropped 28.4% in 2025.
  • Tracing TXG's Share-based Compensation over 5 years: stood at $26.9 million in 2021, then soared by 52.3% to $41.0 million in 2022, then fell by 5.02% to $38.9 million in 2023, then fell by 16.39% to $32.5 million in 2024, then dropped by 22.5% to $25.2 million in 2025.
  • Business Quant data shows Share-based Compensation for TXG at $25.2 million in Q4 2025, $25.3 million in Q3 2025, and $27.6 million in Q2 2025.